SOURCE: Plandai Biotechnologies Inc

February 17, 2012 08:30 ET

Plandai Biotechnology, Inc. Highlights Health Benefits, Advantages of Green Tea Extract Process Cited in Murphy Analytics Report

SEATTLE, WA--(Marketwire - Feb 17, 2012) - Plandaí Biotechnology, Inc. (OTCBB: PLPL) today commented on the Murphy Analytics, LLC research report issued February 8, 2012 that initiated a buy recommendation with a twelve-month price potential of $2.20 per share.

Roger Duffield, Chief Executive Officer of Plandaí, stated, "The Murphy report touches many of the highlights about the market for green tea extract and the unique position of Plandaí within that market. Our proprietary and superior extraction method sets us apart as a leader in the growing field of phytonutrient-rich extracts."

The report states, in part, the following:

The Company's Phytofare™ Green Tea Gallate Catechin Extract is processed to deliver highly bioavailable, phytonutrient-rich extracts to a level many times that of other green tea extracts. In pharmaceutical usage, a higher degree of bioavailability means the requisite quantity of phytonutrients may be delivered in dosages that are feasible for human consumptions without the risk of chemical reaction possible from synthetic analogs. If achieved, this higher bioavailability may make some of the possible uses of green tea extract practically realistic.

The report cited a Coca-Cola-supported research report on the use of polyphenols, stating, "A report in the Journal of Agricultural and Food Chemistry highlights that a polyphenol rich juice can effectively deliver the intended blend of bioavailable polyphenols which would normally require consumption of several different plant-derived foods and drinks."

The report also cited The National Center for Complementary and Alternative Medicine (NCCAM), explaining, "green tea extracts, such as its component EGCG, have been used to prevent and treat a variety of cancers, including breast, stomach, and skin cancers and have also been used for improving mental alertness, aiding in weight loss, lowering cholesterol levels, and protecting skin from sun damage."

The report concludes by citing a study on the processing technology utilized by Plandaí that found that, "Extractable lycopene and other carotenoids increased significantly... Extraction using this proprietary method increased extracted cis-lycopene to as high as 43% of the total lycopene, indicating increased isomerisation. This method could therefore contribute significantly to the delivery of health benefits of biologically available lycopene from tomato products for metabolic functions."

Mr. Duffield added, "The Murphy report illustrates the position of green tea extract as a valuable resource in the fields of nutritional supplements and biomedicine. Plandaí's proprietary technology releases phytonutrients from live plant material in a more absorbable form, thereby increasing the efficacy and lowering the overall cost of an end user product. Plandaí is ideally positioned within the market as a raw material producer and a proprietary developer of consumable product that has proven health benefits in a rapidly expanding market."

For a detailed review of the Murphy research report and valuation methodology, investors are directed to http://www.murphyanalytics.com/uploads/PLPL_Initiation.pdf.

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc., through its recent acquisition of Global Energy Solutions, Ltd. and its subsidiaries, focuses on the farming of whole fruits, vegetables and live plant material and the production of proprietary functional foods and botanical extracts for the health and wellness industry. Its principal holdings consist of land, farms and infrastructure in South Africa.

Safe Harbor Statement
This press release contains forward-looking statements that involve risks and uncertainties. Actual results, events and performances could vary materially from those contemplated by these forward-looking statements. These statements involve known and unknown risks and uncertainties, which may cause the Company's actual results, expressed or implied, to differ materially from expected results. These risks and uncertainties include, among other things, product demand and market competition. You should independently investigate and fully understand all risks before making an investment decision.

Contact Information

  • Contact
    Investor Relations
    Tel: (425) 466-0212
    Email: Email Contact